Relevant bibliographies by topics / Primary cytoreductive surgery

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers
  5. Reports

Academic literature on the topic 'Primary cytoreductive surgery'

Author: Grafiati
Published: 3 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Primary cytoreductive surgery.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Primary cytoreductive surgery"

1

Gerestein, Cornelis G., Dirkina W. van der Spek, Marinus J. Eijkemans, Jeanette Bakker, Geertruida S. Kooi, and Curt W. Burger. "Prediction of Residual Disease After Primary Cytoreductive Surgery for Advanced-Stage Ovarian Cancer: Accuracy of Clinical Judgment." International Journal of Gynecologic Cancer 19, no. 9 (2009): 1511–15. http://dx.doi.org/10.1111/igc.0b013e3181bf82be.

Full text
Abstract:
Objectives:Treatment of patients with an advanced-stage epithelial ovarian cancer (EOC) is based on cytoreductive surgery and platinum-based chemotherapy. Amount of residual disease after primary cytoreductive surgery is an important prognostic factor.The objectives of the present study were to evaluate the accuracy and reproducibility of preoperative clinical judgment of residual disease after primary cytoreductive surgery and to compare the predictive performance of the offhand assessment to the predictive performance of prediction models.Materials and Methods:Fifteen observers (5 gynecologi
APA, Harvard, Vancouver, ISO, and other styles
2

Li, Yiu-Tai, Szu-Ting Yang, and Peng-Hui Wang. "Primary cytoreductive surgery or interval cytoreductive surgery." Taiwanese Journal of Obstetrics and Gynecology 63, no. 6 (2024): 811–13. http://dx.doi.org/10.1016/j.tjog.2024.09.003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dottino, Joseph A., Weiguo He, Charlotte C. Sun, et al. "National trends in bowel and upper abdominal procedures in ovarian cancer surgery." International Journal of Gynecologic Cancer 30, no. 8 (2020): 1195–202. http://dx.doi.org/10.1136/ijgc-2020-001243.

Full text
Abstract:
ObjectivesIn the United States, trends in the initial treatment approach for ovarian cancer reflect a shift in paradigm toward the increased use of neoadjuvant chemotherapy and interval cytoreductive surgery. The aim of this study was to evaluate the trends in surgical cytoreductive procedures in ovarian cancer patients who underwent either primary or interval cytoreductive surgery.MethodsThis retrospective, population-based study examined patients with stage III/IV ovarian cancer diagnosed between January 2000 and December 2013 identified using SEER-Medicare. Small or large bowel resection, o
APA, Harvard, Vancouver, ISO, and other styles
4

Csikos, Csaba, Péter Czina, Szabolcs Molnár, Anna Rebeka Kovács, Ildikó Garai, and Zoárd Tibor Krasznai. "Predicting Complete Cytoreduction with Preoperative [18F]FDG PET/CT in Patients with Ovarian Cancer: A Systematic Review and Meta-Analysis." Diagnostics 14, no. 16 (2024): 1740. http://dx.doi.org/10.3390/diagnostics14161740.

Full text
Abstract:
The cornerstone of ovarian cancer treatment is complete surgical cytoreduction. The gold-standard option in the absence of extra-abdominal metastases and intra-abdominal inoperable circumstances is primary cytoreductive surgery (CRS). However, achieving complete cytoreduction is challenging, and only possible in a selected patient population. Preoperative imaging modalities such as [18F]FDG PET/CT could be useful in patient selection for cytoreductive surgery. In our systematic review and meta-analysis, we aimed to evaluate the role of preoperative [18F]FDG PET/CT in predicting complete cytore
APA, Harvard, Vancouver, ISO, and other styles
5

Memarzadeh, S., S. B. Lee, J. S. Berek, and R. Farias-Eisner. "CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer." International Journal of Gynecologic Cancer 13, no. 2 (2003): 120–24. http://dx.doi.org/10.1136/ijgc-00009577-200303000-00003.

Full text
Abstract:
The utility of preoperative CA125 to predict optimal primary tumor cytoreduction in patients with advanced (stages IIIC and IV) epithelial ovarian cancer is controversial. In this paper, we retrospectively review patients with stage IIIC and IV epithelial ovarian cancer who underwent primary cytoreductive surgery from 1989 to 2001. Ninety-nine patients were identified and included in the analysis. All patients had preoperative CA125 levels measured. Operative and pathology reports were reviewed. Optimal cytoreduction was defined as largest volume of residual disease < 1 cm in maximal dimens
APA, Harvard, Vancouver, ISO, and other styles
6

Koole, Simone, Ruby van Stein, Karolina Sikorska, et al. "Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial." International Journal of Gynecologic Cancer 30, no. 6 (2020): 888–92. http://dx.doi.org/10.1136/ijgc-2020-001231.

Full text
Abstract:
BackgroundThe addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery improves recurrence-free and overall survival in patients with FIGO stage III ovarian cancer who are ineligible for primary cytoreductive surgery. The effect of HIPEC remains undetermined in patients who are candidates for primary cytoreductive surgery.Primary objectiveThe primary objective is to evaluate the effect of HIPEC on overall survival in patients with FIGO stage III epithelial ovarian cancer who are treated with primary cytoreductive surgery resulting in no residual disease,
APA, Harvard, Vancouver, ISO, and other styles
7

Nam, J. H., Y. M. Kim, M. H. Jung, et al. "Primary peritoneal carcinoma: experience with cytoreductive surgery and combination chemotherapy." International Journal of Gynecologic Cancer 16, no. 1 (2006): 23–28. http://dx.doi.org/10.1136/ijgc-00009577-200601000-00004.

Full text
Abstract:
The objective of this study was to review the clinical outcome and prognosis of patients with primary peritoneal carcinoma (PPC) treated with cytoreductive surgery and combination chemotherapy. We retrospectively reviewed the charts of 27 patients with histologically confirmed PPC, treated between March 1990 and February 2004 at Asan Medical Center, South Korea. The review included demographic data, pathologic findings, treatments, and outcomes. The mean age of the 27 patients was 57.5 ± 7.2 years, and the rate of optimal cytoreduction was 70.4%. Seven patients had stage IIIB, 17 had stage III
APA, Harvard, Vancouver, ISO, and other styles
8

Wright, Alexi A., Kari Bohlke, Deborah K. Armstrong, et al. "Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline." Journal of Clinical Oncology 34, no. 28 (2016): 3460–73. http://dx.doi.org/10.1200/jco.2016.68.6907.

Full text
Abstract:
Purpose To provide guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer. Methods The Society of Gynecologic Oncology and the American Society of Clinical Oncology convened an Expert Panel and conducted a systematic review of the literature. Results Four phase III clinical trials form the primary evidence base for the recommendations. The published studies suggest that for selected women with stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and interval cytoreduction are no
APA, Harvard, Vancouver, ISO, and other styles
9

Lūža, Tomas, Agnė Ožalinskaitė, and Vilius Rudaitis. "The rate and role of diaphragmatic peritonectomy in optimal cytoreduction in patients with advanced stage ovarian cancer: a prospective study of 100 patients." Acta medica Lituanica 21, no. 1 (2014): 1–7. http://dx.doi.org/10.6001/actamedica.v21i1.2882.

Full text
Abstract:
Background. Diaphragmatic peritoneal metastasis by advanced epi­thelial ovarian cancer is a very common holdback precluding optimal cytoreduction. The aim of this study was to determine the rate of dia­phragmatic peritonectomy during optimal cytoreductive surgery and its role in postoperative morbidity and survival in patients with advanced ovarian cancer. Materials and methods. 100 consecutive patients with advanced epithelial ovarian cancer underwent cytoreductive surgery and were followed up prospectively (January 2009 – March 2014). Characteristics of surgery, rate of diaphragmatic periton
APA, Harvard, Vancouver, ISO, and other styles
10

Gockley, Allison Ann, Stephen Fiascone, Katherine Hicks Courant, et al. "Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma." International Journal of Gynecologic Cancer 29, no. 3 (2019): 585–92. http://dx.doi.org/10.1136/ijgc-2018-000154.

Full text
Abstract:
ObjectiveThere are limited data on clinical outcomes of patients with advanced-stage epithelial ovarian cancer who require ostomy formation at the time of either primary cytoreductive surgery or interval cytoreductive surgery. The objective of this study was to evaluate patients undergoing bowel surgery and ostomy formation after primary or interval surgery.MethodsPatients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC-IV epithelial ovarian cancer who underwent cytoreductive surgery between January 2010 and December 2014 were identified retrospectively. Patients w
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Primary cytoreductive surgery"

1

PEIRETTI, MICHELE. "Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: surgical and oncological outcomes. single institution experience." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2010. http://hdl.handle.net/10281/8049.

Full text
Abstract:
Objective. The objective of the present study was to determinate the impact of maximal cytoreductive surgery on progression free survival, overall survival rates and morbidity, in patients with advanced epithelial ovarian or fallopian tube cancer (stage IIIC-IV) treated in a referral cancer center. Methods. After obtaining Institutional Review Board approval, we reviewed all medical records of patients with stage IIIC–IV epithelial ovarian cancer who were managed at our institution between January 2001 and December 2008. Individual records were reviewed and the following information collected
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Primary cytoreductive surgery"

1

Besses, Carlos, Beatriz Bellosillo, Alberto Alvarez-Larrán, and Tariq I. Mughal. "Essential thrombocythaemia." In Oxford Specialist Handbook: Myeloproliferative Neoplasms. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198744214.003.0010.

Full text
Abstract:
Essential thrombocythaemia is a classic myeloproliferative neoplasm characterized by thrombocytosis, increased risk of thrombotic and/or haemorrhagic complications, and a trend to transformation to myelofibrosis and acute leukaemia. Mutations in JAK2, CALR, and MPL genes besides bone marrow histology are crucial elements of diagnosis. Treatment is aimed to prevent the appearance of thrombotic complications that are the main cause of morbidity and mortality. Accordingly, thrombosis risk stratification is of the utmost importance to select the appropriate treatment. Antiplatelet therapy as prima
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Primary cytoreductive surgery"

1

Mukhopadhyay, Asima, Basumita Chakraborti, Anik Ghosh, and Jaydip Bhaumik. "Implementing quality indicators for cytoreductive surgery in ovarian cancer: Experience from a tertiary referral center in Eastern India." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685291.

Full text
Abstract:
Background: Debate continues whether primary surgery or neo-adjuvant chemotherapy (NACT) or primary debulking surgery (PDS) should be offered in advanced epithelial ovarian cancer as frontline therapy. Since 2015, there has been a paradigm shift at Tata Medical center, whereas increasing number of patients are being offered PDS and a quality improvement programme was initiated. Recently, ESGO in October 2015 has published a document indicating 10 quality indicators for cytoreductive surgery in advanced ovarian cancer surgery. Aim: We compared our performance against all 10 quality indicators.
APA, Harvard, Vancouver, ISO, and other styles
2

Shahabuddin, Y., R. Daly, C. Thompson, and N. Gleeson. "EP981 Cytoreductive surgery for tubo-ovarian carcinoma – a study of surgical outcomes with primary surgery." In ESGO Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/ijgc-2019-esgo.1027.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Akilli, H., L. Aksoy Karakaş, H. Nihan, and A. Ayhan. "EP773 Splenectomy as primary cytoreductive surgery in advanced stage epithelial ovarian cancer." In ESGO Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/ijgc-2019-esgo.824.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Nakka, Thejeswar, Prasanth Ganesan, Luxitaa Goenka, et al. "Epithelial Ovarian Cancer: Real-World Outcomes." In Annual Conference of Indian Society of Medical and Paediatric Oncology (ISMPO). Thieme Medical and Scientific Publishers Pvt. Ltd., 2021. http://dx.doi.org/10.1055/s-0041-1735369.

Full text
Abstract:
Abstract Introduction Ovarian cancer is the third most common cancer and the second most common cause of death among gynecological cancers in Indian women. Ovarian cancer is heterogeneous, among them, epithelial ovarian cancer (EOC) is the most common. Primary cytoreductive surgery along with six to eight cycles of a combination of platinum and taxanes chemotherapy is the cornerstone of first-line treatment in EOC. This study was done to find clinicopathological factors affecting survival outcomes with first-line therapy in EOC in a real-world setting. Objectives This study was aimed to find f
APA, Harvard, Vancouver, ISO, and other styles
5

Zuo, J., L. Wu, and J. Dai. "EP1044 Preoperative computed tomography predict unresectability in primary cytoreductive surgery for advanced ovarian cancer." In ESGO Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/ijgc-2019-esgo.1087.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kittikhun, Ruai, Witsarut Apikijmeta, and Suttida Intharaburan. "Preoperative evaluation for prediction of suboptimal primary cytoreductive surgery in advanced-stage ovarian cancer." In The 7th Biennial Meeting of Asian Society of Gynecologic Oncology. Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology, 2021. http://dx.doi.org/10.3802/jgo.2021.32.s1.o26.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Daly, R., Y. Shahabuddin, C. Thompson, and N. Gleeson. "EP1203 Cytoreductive surgery for tubo-ovarian carcinoma - a study of MDT decision-making for primary vs NACT-interval surgery." In ESGO Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/ijgc-2019-esgo.1240.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Corry, Edward, Amy Hawarden, Claire Thompson, et al. "EV241/#929 Ensuring a consistent surgical approach for primary cytoreductive surgery for epithelial ovarian cancer." In IGCS 2024 Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2024. https://doi.org/10.1136/ijgc-2024-igcs.360.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Puente, R., and E. Schneider. "EP958 Effectiveness of diaphragmatic curettage in cytoreductive surgery of epithelial ovarian cancer or primary peritoneal malignancy." In ESGO Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/ijgc-2019-esgo.1004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Atallah, D., K. Abi Farraj, M. Moubarak, N. El Kassis, and G. Chahine. "EP933 Thromboembolic events post cytoreductive surgery in patients with ovarian, fallopian tube or primary peritoneal cancer." In ESGO Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/ijgc-2019-esgo.979.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Primary cytoreductive surgery"

1

Kengsakul, Malika, Gatske Nieuwenhuyzen – de Boer, and Heleen van Beekhuizen. Radiological factors associated with residual disease after cytoreductive surgery for advanced ovarian cancer. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.1.0059.

Full text
Abstract:
Review question / Objective: Which radiological factors associated with incomplete cytoreduction (gross residual disease) after cytoreductive surgery (CRS) for advanced ovarian cancer? Condition being studied: Findings of CT scan and discussion in the multidisciplinary tumor board meeting (MDO) are crucial to determine the therapeutic strategy for individual ovarian cancer patients. Preferably, patients undergo primary cytoreductive surgery (CRS) followed by adjuvant chemotherapy. However, when complete cytoreduction is not considered feasible, neoadjuvant chemotherapy followed by interval cyt
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Primary cytoreductive surgery' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography